Paul Klekotka Selected Research

Ulcerative Colitis

1/2020

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Klekotka Research Topics

Disease

19	COVID-19 11/2023 - 01/2021
9	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2020 - 07/2012
3	Infections 10/2023 - 01/2021
2	Atopic Dermatitis (Atopic Eczema) 10/2022 - 09/2020
2	Crohn Disease (Crohn's Disease) 07/2017 - 11/2016
1	Post-Acute COVID-19 Syndrome 01/2023
1	Disease Progression 10/2021
1	Immediate Hypersensitivity 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Urinary Tract Infections (Urinary Tract Infection) 01/2021
1	Ulcerative Colitis 01/2020
1	Hemorrhage 01/2020
1	Inflammation (Inflammations) 12/2016
1	Chronic Obstructive Pulmonary Disease (COPD) 07/2016
1	Lung Diseases (Lung Disease) 07/2016
1	Asthma (Bronchial Asthma) 12/2015
1	Candidiasis (Moniliasis) 10/2015
1	Body Weight (Weight, Body) 10/2015
1	Neutropenia 10/2015
1	Psoriatic Arthritis 03/2015
1	Erythema 07/2012

Drug/Important Bio-Agent (IBA)

16	bamlanivimabIBA 11/2023 - 01/2021
14	Monoclonal AntibodiesIBA 11/2023 - 10/2015
7	brodalumabIBA 01/2020 - 11/2014
5	Antiviral Agents (Antivirals)IBA 01/2023 - 09/2021
4	Interleukin-17 ReceptorsIBA 01/2020 - 11/2014
3	Neutralizing AntibodiesIBA 10/2023 - 01/2021
3	RNA (Ribonucleic Acid)IBA 01/2023 - 12/2021
3	bamlanivimab and etesevimab drug combinationIBA 01/2022 - 01/2021
3	etesevimabIBA 01/2022 - 01/2021
3	Interleukin-17 (Interleukin 17)IBA 01/2020 - 01/2013
3	CytokinesIBA 07/2017 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 12/2015
2	remdesivirIBA 01/2022 - 11/2021
2	AntigensIBA 01/2022 - 12/2021
2	Interleukin-23 (Interleukin 23)IBA 01/2020 - 07/2017
2	Ustekinumab (CNTO 1275)FDA Link 01/2020 - 10/2015
1	Messenger RNA (mRNA)IBA 11/2023
1	EpitopesIBA 11/2023
1	Therapeutic UsesIBA 11/2023
1	Viral RNAIBA 10/2023
1	Immunoglobulin G (IgG)IBA 12/2022
1	Interleukin-33IBA 10/2022
1	Nucleic AcidsIBA 12/2021
1	VaccinesIBA 10/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2021
1	Immunoglobulin A (IgA)IBA 09/2020
1	mirikizumabIBA 01/2020
1	MEDI2070IBA 07/2017
1	Tumor Necrosis Factor InhibitorsIBA 07/2017
1	GoldIBA 07/2016
1	Indicators and Reagents (Reagents)IBA 12/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2015
1	Immunoglobulin E (IgE)IBA 12/2015
1	Bronchodilator Agents (Bronchodilators)IBA 12/2015
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2013
1	Etanercept (Enbrel)FDA Link 07/2012

Therapy/Procedure

9	Therapeutics 01/2023 - 03/2015
2	Intravenous Infusions 10/2021 - 01/2021
1	Aftercare (After-Treatment) 01/2023
1	Retreatment 01/2020
1	Biological Therapy 07/2012
1	Subcutaneous Injections 07/2012